A First-in-Man Clinical Evaluation of Sirolimus and Ascorbic Acid-Eluting Stent Systems: a Multicenter, Subject-Blinded, Randomized Study
- Authors
- Lim, Young-Hyo; Youn, Ji Hyun; Hong, Soon-Jun; Ahn, Tae-Hoon; Yoon, Junghan; Park, Jun-Kyu; Kim, Hyo-Soo
- Issue Date
- Dec-2021
- Publisher
- 대한심장학회
- Keywords
- Drug-eluting stents; Sirolimus; Ascorbic acid; Coronary artery disease; Absorbable implants
- Citation
- Korean Circulation Journal, v.51, no.12, pp 1001 - 1014
- Pages
- 14
- Indexed
- SCIE
SCOPUS
KCI
- Journal Title
- Korean Circulation Journal
- Volume
- 51
- Number
- 12
- Start Page
- 1001
- End Page
- 1014
- URI
- https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/54960
- DOI
- 10.4070/kcj.2021.0161
- ISSN
- 1738-5520
1738-5555
- Abstract
- Background and Objectives
This clinical trial was conducted to evaluate the safety and efficacy of D+Storm™ drug-eluting stent (DES) and BioMatrix Flex™ DES.
Methods
This study was a multicenter, subject-single-blind, randomized, and confirmed comparative clinical trial. According to the inclusion criteria, those diagnosed with stable angina, unstable angina, silent ischemia, or non-ST-segment myocardial infarction were selected among patients with coronary artery stenosis as subjects. Among the subjects with 50% stenosis on coronary angiography, the experiment was performed on those who had a lesion with reference vessel 2.5–4.0 mm in diameter and ≤40 mm in length. The primary endpoint was an in-segment late loss and the secondary endpoints were in-stent late lumen loss, stent malapposition, the incidence of mortality, myocardial infarction, reoperation, and stent thrombosis at 36 weeks.
Results
57 patients in the D+Storm™ DES group and 55 patients in the BioMatrix Flex™ DES group were enrolled in the study. Fifty-seven patients in the D+Storm™ DES group and Fifty-five patients in the BioMatrix Flex™ DES group were enrolled in the study. An average of in-segment late lumen loss was 0.08±0.13 mm in the D+Storm™ DES group and 0.14±0.32 mm in the BioMatrix Flex™ DES group with no significant difference between the 2 groups (p=0.879). In addition, there was no significant difference in adverse events between D+Storm™ DES and BioMatrix Flex™ DES.
Conclusions
This study demonstrated the clinical effectiveness and safety of D+Storm™ DES implantation in patients with coronary artery disease over a 36-week follow-up period.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 2. Clinical Science > Department of Cardiology > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.